SEC Tracker
Get the app

Cara Therapeutics TVRD

Cara Therapeutics Q3 FY23: revenue $4.9M; diluted EPS −$6.27

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Cara Therapeutics reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$4.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$28.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$6.27No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$0.5210-Q income statement, on EDGAR
  4. Cash and cash equivalents$62.9MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations−$19.6MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Cara Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Silence Therapeutics SLN public float $206M, Jun 30, 2025
  2. Cardiff Oncology CRDF public float $205M, Jun 30, 2025
  3. Rezolute RZLT public float $204M, Dec 31, 2025
  4. Natures Sunshine Products NATR public float $211M, Jun 30, 2025
  5. Rocket Pharmaceuticals RCKT public float $213M, Jun 30, 2025